Business Context and Reporting Period
Company: Insulet Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: June 1, 2023
Reporting Period: Single event date (June 1, 2023)
This filing reports the entry into a material definitive agreement between Insulet Corporation and Amgen Inc. regarding the extension and amendment of their existing supply relationship.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on a contractual agreement rather than periodic financial performance.
Material Changes
- Agreement Amendment: On June 1, 2023, Insulet and Amgen executed Amendment Number 21 to their Supply Agreement originally dated November 21, 2013.
- Scope of Changes: The amendment extends the term of the Original Agreement and modifies definitions and terms related to:
- Manufacturing sites
- Timing and purchase commitments
- Qualification requirements
- Pricing
- Other operational matters
- Intellectual Property: In connection with the amendment, the parties entered into a Patent Assignment and License Agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing provides a summary of the agreement's purpose but does not include forward-looking guidance, earnings outlook, or detailed management commentary on financial impact.
Risks and Contingencies: The filing notes that certain portions of the full text of Amendment 21 (Exhibit 10.1) are considered confidential and have been omitted. No specific risks or contingencies are detailed in the summary text provided.
Investor Verification Checklist
- Review the full text of Exhibit 10.1 (Amendment Number 21) to understand the specific pricing changes and purchase commitment details, as the summary omits confidential portions.
- Verify the new expiration date of the supply agreement with Amgen.
- Assess the impact of the Patent Assignment and License Agreement on Insulet's intellectual property portfolio.
- Confirm if the amendment affects the volume of customized devices Insulet is obligated to manufacture for Amgen.